newsfilter
← Latest News
Business Wire·

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus outlines development strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including the potential to become the first HIF-2a